A detailed history of Principal Securities, Inc. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Principal Securities, Inc. holds 90 shares of BGNE stock, worth $17,127. This represents 0.0% of its overall portfolio holdings.

Number of Shares
90
Previous 95 5.26%
Holding current value
$17,127
Previous $13.6 Million 49.08%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$143.93 - $224.51 $719 - $1,122
-5 Reduced 5.26%
90 $20.2 Million
Q2 2024

Jul 31, 2024

BUY
$129.52 - $174.32 $5,051 - $6,798
39 Added 69.64%
95 $13.6 Million
Q4 2023

Feb 07, 2024

BUY
$158.67 - $201.58 $8,885 - $11,288
56 New
56 $10.1 Million

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $19.7B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Principal Securities, Inc. Portfolio

Follow Principal Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Principal Securities, Inc. with notifications on news.